Guardant Health stock surges on colon cancer blood test news
Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intact. The new price target came less than a day after a ...
The Source
THE STREET
US
Nike unsteady as new legal fight brews
THE STREET·5d ago·3 min read
US
Walmart quietly built a $6 billion business off its shoppers
THE STREET·5d ago·3 min read
US
A big shift in the U.S. energy market is about to happen
THE STREET·5d ago·3 min read
US
Nvidia’s surprising product revival tells deeper AI industry story
THE STREET·5d ago·3 min read
Related
On this beat
US
Nike unsteady as new legal fight brews
THE STREET·5d ago·3 min read
US
Walmart quietly built a $6 billion business off its shoppers
THE STREET·5d ago·3 min read
US
A big shift in the U.S. energy market is about to happen
THE STREET·5d ago·3 min read
US
Nvidia’s surprising product revival tells deeper AI industry story
THE STREET·5d ago·3 min read